BayBio Board Brings Stability to the Life Sciences Community
SOUTH SAN FRANCISCO, Calif. – January 1, 2011—OncoMed Pharmaceuticals CEO Paul Hastings will serve another term as Chairman of the Board of BayBio, Northern California’s life sciences association. In addition, the trade association also announced the appointment of Stanford University’s Michael Alvarez as chair of the BayBio Institute.
Vice Chairs to the two boards were also announced. XOMA President and CEO Steven Engle was elected to a one year term of the BayBio Board of Directors. Bayer HealthCare’s Sreejit Mohan will serve as the BayBio Institute’s vice-chairman. Target Discovery CEO Jeff Peterson will become the BayBio Institute’s chair emeritus.
“Northern California’s life sciences industry is the largest, oldest and most productive life sciences cluster in the world and continues to be a significant source of economic strength and vitality for the State of California,” said Gail Maderis, CEO and president of BayBio. “We will improve biotechnology’s standing in the community and the importance of science education to our students, teachers and elected officials.”
“This is a group of leaders dedicated to advancing new treatments for unmet medical needs and developing new technologies to solve many of the nation’s most pressing health challenges,” added BayBio Chairman Paul Hastings, president and CEO of OncoMed Pharmaceuticals. “Their commitment to serve is recognition and reminder this unique marriage of innovation protects and promotes economic stability for the state and the nation. BayBio serves a central part to us all in strengthening those ties.”
BayBio is an independent, non-profit 501(c)(6) trade association serving the life science industry in Northern California. The staff and services of BayBio are paid primarily through memberships, sponsorships, and event registration fees. BayBio provides these services through representatives in South San Francisco, Emeryville, Sacramento and through coalition partners in Washington, DC.